Controversial Fertility Treatments Focus on Eggs’ Power Plants
By Jennifer Couzin-Frankel,
Science Magazine
| 03. 30. 2015
Untitled Document
Derived from bacteria, mitochondria are our cells’ energy-producing powerhouses. Now, a Massachusetts company is convinced that these microscopic cylinders are also key to conceiving a baby, and it has persuaded several groups of physicians outside the United States to test that controversial premise in women with fertility problems. More than 10 women are pregnant via the firm’s proprietary in vitro fertilization (IVF) method, which adds a bolus of a woman’s own mitochondria to her mature egg.
Meanwhile, the U.S. Food and Drug Administration (FDA) has erected roadblocks in front of a fertility specialist and a stem cell biologist who want to clinically test the mitochondrial hypothesis in the United States. The duo would like to harness a different IVF strategy: swapping out a woman’s mitochondria by transferring chromosomes from her egg into an egg from another woman. The technique, called mitochondrial replacement therapy (MRT), was just legalized in the United Kingdom to prevent rare genetic diseases. But even before that, the two researchers applied for permission to use it in women who are struggling to conceive...
Related Articles
By Rob Stein, NPR [cites CGS' Katie Hasson] | 08.06.2025
A Chinese scientist horrified the world in 2018 when he revealed he had secretly engineered the birth of the world's first gene-edited babies.
His work was reviled as reckless and unethical because, among other reasons, gene-editing was so new...
By Kristel Tjandra, Genetic Engineering & Biotechnology News | 07.30.2025
CRISPR has taken the bioengineering world by storm since its first introduction. From treating sickle cell diseases to creating disease-resistant crops, the technology continues to boast success on various fronts. But getting CRISPR experiments right in the lab isn’t simple...
By Arthur Caplan and James Tabery, Scientific American | 07.28.2025
An understandable ethics outcry greeted the June announcement of a software platform that offers aspiring parents “genetic optimization” of their embryos. Touted by Nucleus Genomics’ CEO Kian Sadeghi, the $5,999 service, dubbed “Nucleus Embryo,” promised optimization of...
By Keith Casebonne and Jodi Beckstine [with CGS' Katie Hasson], Disability Deep Dive | 07.24.2025
In this episode of Disability Deep Dive, hosts Keith and Jodi explore the complex interplay between disability science, technology, and ethics with guest Katie Hasson, Associate Director at the Center for Genetics and Society. The conversation delves into...